OR WAIT 15 SECS
Contract manufacturing organizations need to adapt to successfully overcome the specific challenges posed by complex therapies.
The growth within the field of biologics has been palpable over the past few years and is expected to continue to expand for the foreseeable future. With such a positive outlook, outsourced capabilities may also be able to ride on the crest of the biologics wave, although as reported by Results Healthcare, contract manufacturing organizations (CMOs) may need to consider subsector patterns to take advantage of the market shifts.
BioPharm International spoke with Mike Danzi, CEO of Legacy Pharmaceuticals Switzerland, which is a SwissMedic and US FDA-approved CMO, about the challenges facing CMOs in the field of biologics and best practices for working with complex therapies.
eBook: Outsourcing Resources 2019
When referring to this article, please cite it as F. Thomas, "Navigating the Biologics Wave," BioPharm International's Outsourcing Resources eBook (April 2019).